After Cerner made a recent investment in Seattle-based startup Xealth, the two companies rolled out new capabilities to make digital health tools easier to deploy. One of Cerner’s clients, Phoenix-based Banner Health, is rolling it out to help its physicians prescribe and monitor digital health tools.
Most digital health recommendations still involve handing patients brochures or asking them to download something from an app store, Xealth CEO Mike McSherry wrote in an email.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
“Without Xealth, clinicians would recommend a tool and the rest was up to the patient,” McSherry wrote. “Some apps do have a clinician view offering some metrics, although most do not tie into prescribing data and are in stand-alone dashboards, requiring the clinician to actively seek out data as well as remember various different passwords to different systems and portals.”
Xealth works with more than 30 different digital health solutions, from platforms for managing chronic conditions like Omada, to virtual behavioral health provider SilverCloud.
It integrates directly into electronic health record systems, allowing physicians to place and send orders for digital programs directly to patients’ smartphones. Within the EHR, they can monitor patients’ responses in a dashboard, which can be filtered to present the most relevant information to care teams.
Xealth is already integrated with Cerner’s biggest competitor, Epic, making its platform available to more than half of U.S. hospitals.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
“We are open to integrating with more EHRs as customer demand warrants,” McSherry wrote.
Photo credit: Venimo, Getty Images
